The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Category Archives: Jeremy Grushcow

Biotech Trends Update — Biosimilars Blur IP Constituencies: Novartis and Pfizer-Biocon are Featured in the Economist

Two 9-figure announcements this week mark a turning point for the biosimilars market, and one highlights the increasingly important role India plays in innovation. Pfizer linked up with India’s Biocon in a deal that will see Biocon take the lead in development of four biosimilar insulin products that gives Biocon $200 million up front. Coverage of [...]

This Week in the Twitterverse

Lots of great weekend reading from our Twitter stream on @crossborderbio, including news and commentary on the latest in personalized medicine and the Canadian VC landscape: RT @LillyPad: ..changing R&D models to develop more targeted therapies instead of blockbusters, tailoring therapies that are more effective. 1 day ago RT @wellingtonfund WF-Blog:Mass confusion in ventureland: Is the venture model “broken”? [...]

Biotech Trends Update — Personalized Medicine: Duncan’s Personalized Health Manifesto is Primarily Preventative

Journalist David Ewing Duncan’s “Personalized Health Manifesto” was published this week by the Ewing Marion Kauffman Foundation. The most interesting thing about the manifesto* is that it assumes that the technical hurdles to generating and understading a full set of personalized health data have been overcome, and focuses on how that information can be deployed [...]

Biotech Trends Update — Biosimilars: FDA Meeting Formally Announced, EMA Working on Rules for (a few) Antibody Biosimilars

Reuters reports that the European Medicines Agency (EMA), which has already approved 13 biosimilars, is expecting to publish guidelines in November on biosimilar antibody therapeutics. EMA Executive Director Thomas Lonngren said that clinical trials will be required for antibody biosimilars (as they are for the products EMA has approved to date), but that requirements were [...]

Canadian Venture Capital Data from Q2 2010 Shows Big Jump From Q2 2009 but Only Moderate Increase for Biotech

The Q2 issue of Industry Canada’s Venture Capital Monitor is up, and it shows “the highest level of VC activity since Q3 2008,” though that is still “significantly lower than the quarterly average of $440M recorded over the previous five years before the downturn.” A couple of (particularly) parochial notes: First-time deals at the seed and [...]

This Week in the Twitterverse

Here’s some weekend reading from our Twitter stream on @crossborderbio … Friday Science Review is back, thx to Mark Curtis! Today’s cool Canadian science = tomorrow’s cool startups… http://ow.ly/19f2te1 DTC genetics link in last tweet is from @CMAJ_News – also contrasts Class III regulation of companion diagnostics. I.e. DTC is non-clinical? MT @genomicslawyer: …Health Canada is taking [...]

More OETF Investments Announced, Including NeurAxon

The Ontario Emerging Technologies Fund got off to a bit of a slow start on the life sciences front, but last month it added Lumira and CTI Life Sciences as qualified investors. Now, CTI has taken advantage of that status with OETF participating in a $14 million round of convertible debentures issued by NeurAxon, along [...]

Biotech Trends Update — IP Constituencies: Endo’s Qualitest Purchase Shows Full Integration of Innovator and Generic Strategies

Endo Pharmaceuticals (NASDAQ: ENDP) announced yesterday morning that it will spend $1.2 billion to buy U.S. generics company Qualitest Pharmaceuticals. Endo also has an active pipeline of “innovative” products in development, emphasizing the industry trend we’ve been following of a narrowing distinction between innovator and generics companies. Endo began its modern existence after being spun [...]

This Week in the Twitterverse

Lots of great weekend reading from our Twitter stream on @crossborderbio, including a plane that flies like a bird, a $450 million licensing deal and links to several worthwhile upcoming events:

Cross-Border Biotech Blog News: Favourite Features Returning With New Authors

I’m excited to announce that the Monday Biotech Deal Review and the Friday Science Review will be back next week to restart your regular dosing of Canada’s Biotech inventions and transactions. The Monday Deal Review will be authored by Jacob Cawker, who has worked with me on the blog in various capacities over the past three years. [...]

Why Technology Transfer Offices Should Focus on Sponsored Research and Ignore Royalties: In Praise of UNC’s “Express License”

A story by Xconomy’s Sylvia Pagán Westphal yesterday highlights a new approach to technology transfer licensing being taken by UNC Chapel Hill’s Office of Technology Development: The Carolina Express License. At first glance, the agreement looks, as Westphal puts it, “not very sweet for the university.” UNC takes 0.75% of any exit transaction, but no equity, no milestones [...]

Biotech Trends Update — Biosimilars: FDA Meeting in November to Discuss BCPI Act Implementation

Adam Feuerstein at TheStreet.com reported this morning on a draft FDA notice for a planned November meeting on implementation of the Biologics Price Competition and Innovation Act, which was passed as part of the healthcare reform legislation. The BPCI Act (42 U.S.C. 262(k)(8)) provides for the FDA to author guidance “with respect to the licensure [...]

Flow-Through Shares for Biotech: Welcome to National Biotechnology Week in Canada

Tomorrow is the first day of National Biotechnology Week in Canada. The imagenation.ca website has lots of info, and you can follow @BIOTECanadaNBW on Twitter. One of this year’s big policy initiatives is a push to expand Canada’s Flow-Through Shares program from mining and wind power to include biotech and other cleantech companies. I gave [...]

Agricultural Biotechnology International Conference (ABIC) In Saskatoon This Week Highlights Canada’s Strength in Ag-Biotech

The ABIC conference in Saskatoon this week is highlighting Canada’s strength in the field (har). Canada has world-class resources to compete: plenty of arable and marginal land, and bushels (sorry) of know-how and innovation. Two Canadian announcements of note at the conference: Saskatchewan’s Premier, Brad Wall, announced $5 million over 4 years for ag-bio projects. The [...]

Gone Fishing

I am taking a break from the online world for a couple of weeks and will be back after Labo(u)r Day. Until then, check out the industry trends pages or my Twitter list of biopharma and health news sources. See you in September!

Monday Biotech Deal Review: August 16, 2010

Another decent week for Canada’s biotech companies, with about $30 million of securities sold and more deals launched. Big headlines this week for Alectos’ Alzheimer’s collaboration with Merck, which gets a US$289 million number but declines to split out the up-front payment or other details of the fee structure. Also, eHealth Ontario is spending significant [...]

This Week in the Twitterverse

Here’s some reading for the weekend from our Twitter stream on @crossborderbio: RT @FiercePharma: Genomics might have rescued Sanofi diet drug.http://bit.ly/d18EFp 14 hours ago YM Biosciences’ Phase II JAK1/2 inhibitor gets orphan drug designation for myelofibrosis http://bit.ly/aFD4xc1 day ago Final Call for Abstracts (Deadline Extended): Canadian Science Policy Conference 2010 – Deadline Aug 29th, 2010 http://bit.ly/9EB34b 2 days ago Merck in Canada: $289m Alzheimer’s [...]

Ontario Emerging Technologies Fund (OETF) Shows Signs of Life (Sciences), Adds Biotech Investments and Investors

An announcement this morning from the OETF — Ontario’s (née) $250 million co-investment fund – shows positive signs for potential matching investments in the life sciences. First, the OETF announced an investment in Natrix Separations. BDC wore the “Qualified Investor” hat on that one, but Natrix is in GrowthWorks’ Canadian Fund portfolio, so we know at [...]

Monday Biotech Deal Review: August 9, 2010

Catching up from the long weekend last week, we have a full two weeks’ worth of deals to bring you. Highlights include $16.7 million of securities closings, $8.25 million launched; and interesting developments in the Forbes Medi-Tech and Northstar Healthcare acquisitions. Check out what the last two weeks have wrought…

This Week in the Twitterverse

Even though posts have dropped off between the long weekend last week and some business travel, I’ve been keeping Twitter up to date and will resume with a two-week deal review on Monday. In the meantime, here’s some reading to catch up on: RT @PharmProEditor: Patheon Signs Technology Transfer Agreement with Dendreon http://bit.ly/aWElIg RT @OntInnovation: RT [...]

FedDev Ontario is Feeding $45 million Through NRC-IRAP to Support SMB Innovation

During a visit to Sernova (TSXV: SVA) today, Gary Goodyear* announced that $45 million of FedDev Ontario money will be deployed through the NRC’s Industrial Research Assistance Program (IRAP). IRAP has been a relatively effective vehicle for funding life science companies and has taken a prominent role since having been allocated $200 million in the 2009 federal [...]

Monday Biotech Deal Review: July 26, 2010

Things were interesting for Forbes Medi-Tech (or at least its creditors), which saw a new bidder emerge for its assets. A few placements and other deals closed, some lower than expected. See who made it through the heat without wilting this week

Monday Biotech Deal Review: July 19, 2010

Lots of deals this week. Some good news, some bad news. On the good news front, a steady volume of securities and M&A activity is continuing through the summer; and one Canadian firm benefits from the U.S. Defense Departments exploration of RNAi products as anti-virals. On the other hand front, though, a licensing option expired, a liquidation proceeded [...]

This Week in the Twitterverse

Here’s some reading for the weekend from our Twitter stream on @crossborderbio: via @Michael_Gilman and @pearlf, great advice on running effective board mtgs http://j.mp/bkbjbh  U.S. Defense Dept Transformational Medical Tech program funds 2 RNAi projects: BC’s Tekmira http://bit.ly/cpOa8U & AVI http://bit.ly/ckCCxU  RT @FiercePharma: Reuters: Glaxo, Pfizer JV opens HIV pipeline to generic cos. http://bit.ly/adLi9x  RT @genomicslawyer: [...]

E&Y Beyond Borders Biotech Report 2010 — Canadian Biotech Data

I went to Ernst & Young‘s Toronto presentation of this year’s Beyond Borders global biotech report (pdf) this morning. The report is a retrospective of 2009, so many of the data points and trends reflect things you’ve seen already; but as always, I’d encourage you to read the whole thing for good synthesis and commentary. E&Y’s [...]

Monday Biotech Deal Review: July 12, 2010

This week saw several interesting deals, including an $85+ million exit for Sentinelle, some “bio-bucks” made good for Cipher, a licensing deal for Amorfix’s vCJD technology, a $10 million malaria deal for BC-based Artepharm and a new name (Medwell Capital) to go along with BioMS’ new business model.

This Week in the Twitterverse

As you may have surmised (from my out-of-office email or from my attempts to get the attention of Delta’s customer service tweeps) I was out of town this week. Still, here’s some weekend reading for you from our Twitter stream @crossborderbio: RT @dgmacarthur: July 12 is your last chance to comment on NIH’s planned genetic [...]

Monday Biotech Deal Review: July 5, 2010

Not a bad week for deals, considering the holiday weekend in both Canada and the U.S.. Response Biomedical placed a PIPE with OrbiMed funds, CTI did a follow-on round in Zymeworks and LAB Research took an equity line. Plus a companion diagnostic deal from Aeterna, just as I’m planning for Diagnostics Asia in August. The week’s [...]

This Week in the Twitterverse

Here’s some reading for the weekend from our Twitter stream on @crossborderbio: RT @IBMResearch: Roche and IBM Collaborate to Develop Nanopore-Based DNA Sequencing Technology – http://cot.ag/9vbj8l  RT @CBCHealth: Chalk River reactor to restart in July: AECL http://bit.ly/d66r72  RT @ogilvyrenault: Ogilvy Renault’s Rick Sutin quoted in Financial Post article on TSX/TSXV’s strength in cleantech http://bit.ly/cFAXr2  RT @markrmcqueen [...]

Key Quotes from the U.S. Supreme Court’s Decision in Bilski Shows No Current Impact on Biotech

Many expected the U.S. Supreme Court’s decision in Bilski to have a far-reaching impact on methods patents, including biotechnology diagnostics and drug development. That turned out not to be the case, with the Court deciding on narrow grounds that the actual patent at issue was improperly granted and reminding the Federal Circuit that it prefers [...]

Follow

Get every new post delivered to your Inbox.

Join 92 other followers